Table S1. The classification of clinical diagnosis, histological diagnosis by pathogenesis, and by histopathology in J-RBR in 2010
Clinical diagnosis
Acute nephritic syndrome
Histological diagnosis by pathogenesis
Primary glomerular disease except IgA
Histological diagnosis by histopathology
Minor glomerular abnormalities
nephropathy
Rapidly progressive nephritic syndrome
IgA nephropathy
Focal and segmental glomerulosclerosis
Recurrent or persistent hematuria
Purpura nephritis
Membranous nephropathy
Chronic nephritic syndrome
Lupus nephritis
Mesangial proliferative glomerulonephritis
Nephrotic syndrome
MPO-ANCA positive nephritis
Endocapillary proliferative glomerulonephritis
Renal disorder with metabolic disease
PR3-ANCA positive nephritis
Membranoproliferative glomerulonephritis (types I
and III)
Renal disorder with collagen disease or
Anti-glomerular basement membrane antibody
Dense deposit disease
vasculitis
nephritis
Hypertensive nephropathy
Hypertensive nephrosclerosis
Crescentic and necrotizing glomerulonephritis
Inherited renal disease
Thrombotic microangiopathy
Sclerosing glomerulonephritis
Acute renal failure
Diabetic nephropathy
Nephrosclerosis
Drug-induced nephropathy
Amyloid nephropathy
Acute interstitial nephritis
Renal transplantation
Alport syndrome
Chronic interstitial nephritis
Hemolytic uremic syndrome and thrombotic
Thin basement membrane disease
Acute tubular necrosis
Infection-related nephropathy
Transplanted kidney
Polycystic kidney disease (PKD)a
Transplanted kidney
Others
Others
Others
thrombocytopenic purpura (HUS/TTP)a
Congenital anomalies of the kidney and
urinary tract (CAKUT)a
a, added in 2010.
1
Table S2. Distribution of CKD stages and clinical parameters in male in IgA nephropathy in J-RBR: Combined data of 2009 and 2010
CKD stage
G1
G2
G3a/b
G4
G5
Total
P value*
Male
N (%)
Age, years, average
median
Body mass index
Estimated GFR,
mL/min/1.73m2
299
27.7
22.1 ± 11.2
19 (16 – 25)
21.4 ± 4.7
111.2
(97.2 – 138.2)
0.31
(0.10 – 0.88)
0.38
(0.12 – 0.90)
79.9
0.72
(0.62 – 0.80)
4.23 ± 0.51
180.2 ± 38.9
116.6 ± 14.1
68.1 ± 11.5
16.5
2.8
376
34.8
40.5 ± 14.3
38 (30 – 52)
23.7 ± 3.7
74.0
(67.4 – 82.0)
0.60
(0.24 – 1.19)
0.59
(0.29 – 1.14)
78.2
0.92
(0.86 – 1.00)
4.11 ± 0.53
199.9 ± 42.9
127.8 ± 14.9
77.9 ± 12.2
37.5
3.3
325
30.1
51.7 ± 13.1
54 (42 – 61)
24.0 ± 3.5
49.1
(41.7 – 55.0)
1.01
(0.45 – 2.00)
1.00
(0.48 – 1.83)
72.3
1.29
(1.15 – 1.46)
3.82 ± 0.63
203.9 ± 51.1
130.8 ± 17.8
79.8 ± 12.8
63.0
7.6
62
5.7
60.0 ± 15.9
62 (51 – 73)
23.6 ± 3.8
25.3
(21.2 – 27.5)
1.78
(0.80 – 3.20)
1.68
(0.92 – 4.01)
77.4
2.27
(2.02 – 2.68)
3.41 ± 0.65
205.6 ± 53.2
140.8 ± 22.2
84.2 ± 14.6
79.6
29.3
17
1.6
49.0 ± 21.6
51 (34 – 60)
23.1 ± 4.3
8.6
(5.6 – 13.4)
2.91
(1.09 – 5.00)
2.91
(1.56 – 4.20)
82.4
6.00
(4.04 – 10.0)
3.28 ± 0.58
200.3 ± 45.3
152.0 ± 22.2
89.5 ± 10.2
60.0
0.0
1,083
100.0
40.0 ± 18.3
38 (24 – 56)
23.1 ± 4.1
70.5
(50.8 – 93.0)
0.67
(0.24 – 1.44)
0.70
(0.28 – 1.43)
77.0
0.97
(0.80 – 1.23)
4.00 ± 0.61
195.9 ± 46.3
126.6 ± 17.7
76.3 ± 13.4
42.6
5.9
–
–
< 0.0001
< 0.0001
< 0.0001
Proteinuria, g/day (n)
Proteinuria, g/gCr (n)
Sediment RBC ≥ 5/hpf (%)
Serum creatinine,m g/dL
Serum albumin, g/dL
Serum total cholesterol, mg/dL
Systolic BP, mmHg
Diastolic BP, mmHg
Anti-hypertensive agents, %
Diabetes mellitus, %
< 0.0001
< 0.0001
< 0.0001
0.2016
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
Data are presented as the means ± SD or the medians (interquartile ranges). CKD, chronic kidney disease; GFR, glomerular filtration rate; BP, blood
pressure. *ANOVA, Kruskal-Wallis or 2-test as appropriately. There are four (0.4%) missing value of the CKD stage because of inappropriate data of
serum creatinine.
2
Table S3. Distribution of CKD stages and clinical parameters in female in IgA nephropathy in J-RBR: Combined data of 2009 and 2010
CKD stage
G1
G2
G3a/b
G4
G5
Total
P value*
Female
N (%)
Age, years, average
median
Body mass index
Estimated GFR,
mL/min/1.73m2
364
33.4
24.7 ± 10.5
24 (18 – 30)
20.7 ± 3.3
106.0
(96.4 – 123.0)
0.30
(0.11 – 0.80)
0.40
(0.15 – 0.95)
84.3
0.56
(0.50 – 0.60)
4.09 ± 0.41
188.2 ± 35.8
111.8 ± 13.5
67.2 ± 11.4
11.6
0.4
468
40.2
40.1 ± 12.7
38 (31 – 49)
22.2 ± 3.7
76.3
(68.0 – 83.2)
0.42
(0.20 – 0.94)
0.67
(0.27 – 1.30)
84.0
0.70
(0.64 – 0.75)
3.95 ± 0.44
208.0 ± 48.6
119.4 ± 16.4
72.7 ± 11.9
29.7
2.9
226
20.7
49.7 ± 12.7
49 (42 – 60)
23.0 ± 3.9
49.3
(42.2 – 54.0)
0.85
(0.35 – 1.99)
1.17
(0.58 – 2.48)
77.9
0.97
(0.90 – 1.10)
3.75 ± 0.53
218.7 ± 49.9
129.5 ± 17.5
77.6 ± 12.0
54.5
7.9
49
4.5
50.3 ± 15.1
51 (38 – 63)
22.3 ± 5.1
22.8
(20.4 – 27.7)
1.40
(0.70 – 2.57)
1.75
(0.67 – 5.20)
87.8
1.89
(1.67 – 2.22)
3.49 ± 0.61
219.1 ± 50.6
133.8 ± 22.5
77.2 ± 16.0
71.4
11.4
13
1.2
42.8 ± 18.9
33 (27 – 64)
23.7 ± 7.5
7.76
(6.24 – 11.3)
2.70
(0.94 – 3.65)
3.26
(0.80 – 5.18)
92.3
5.10
(4.10 – 7.24)
3.15 ± 0.63
244.9 ± 64.6
142.6 ± 33.3
86.0 ± 24.3
81.8
0.0
1,094
100.0
37.5 ± 15.7
36 (25 – 49)
21.9 ± 3.9
78.4
(58.2 – 96.7)
0.50
(0.20 – 1.10)
0.70
(0.26 – 1.50)
83.0
0.69
(0.59 – 0.84)
3.93 ± 0.49
204.4 ± 47.0
119.8 ± 17.9
72.2 ± 12.9
31.4
3.4
–
–
< 0.0001
< 0.0001
< 0.0001
Proteinuria, g/day (n)
Proteinuria, g/gCr (n)
Sediment RBC ≥ 5/hpf (%)
Serum creatinine,m g/dL
Serum albumin, g/dL
Serum total cholesterol, mg/dL
Systolic BP, mmHg
Diastolic BP, mmHg
Anti-hypertensive agents, %
Diabetes mellitus, %
< 0.0001
< 0.0001
< 0.0001
0.1633
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
Data are presented as the means ± SD or the medians (interquartile ranges). CKD, chronic kidney disease; GFR, glomerular filtration rate; BP, blood
pressure. *ANOVA, Kruskal-Wallis or 2-test as appropriately. There are four (0.4%) missing value of the CKD stage because of inappropriate data of
serum creatinine.
3